

NEWS RELEASE

IX BIOPHARMA COMMENCES SUPPLY OF WAFESIL[®] AND SILCAP[®] IN AUSTRALIA THROUGH TELEMEDICINE

- **iX Biopharma has commenced the supply of Wafesil[®] and Silcap[®] through telemedicine in Australia, which enables patients to access medical advice and treatment safely, discreetly and conveniently**
- **Telemedicine has recorded rapid adoption amid the Covid-19 pandemic as patients turn to digital health technologies and platforms for medical care**
- **More than 4500 boxes of Wafesil[®] and Silcap[®] have been supplied to patients through telemedicine to-date**

Singapore, 26 May 2020 – iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has commenced supply of Wafesil[®] and Silcap[®], which are medicines for the treatment of male erectile dysfunction, through telemedicine in Australia. The products are supplied to Australian pharmacies and are available to patients by doctors’ prescription.

iX Biopharma has identified telemedicine as an opportune way to reach Australian patients amid their changing behaviours during the Covid-19 pandemic. Telemedicine, where doctors prescribe medication after holding online consultations with patients on digital platforms, is disrupting traditional healthcare and recording unprecedented user growth in 2020¹. The accelerated adoption of telemedicine is in part due to more patients seeking safe and convenient access to medical advice and treatment without the risk of potentially contracting the infectious virus in medical clinics.

An example of a telemedicine platform which prescribes Wafesil[®] and Silcap[®] is *Pilot*, an online men’s health platform that connects men who suffer from health conditions such as erectile dysfunction, with doctors who provide advice and prescribe medication, and pharmacies who ship the medication directly to the patient. Its end-to-end service caters to patients who desire safety, convenience and discretion. More than 4500 boxes of Wafesil[®] and Silcap[®] have been supplied to patients through Pilot’s online health platform to-date.

Erectile dysfunction is a condition that affects approximately 20% of Australian men greater than 40 years old². In addition to the advantages during the pandemic, telemedicine offers an opportunity for iX Biopharma to reach men who would otherwise not seek treatment for erectile dysfunction due to perceived stigma or embarrassment.

Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: *“Today, most people have access to basic telemedicine devices like mobile phones and computers. With improved accessibility, individuals in rural areas and busy urban areas can connect with a healthcare provider with ease.*

¹ Bain & Company, *Covid-19 Accelerates the Adoption of Telemedicine in Asia-Pacific Countries*, accessed 22 May 2020, <https://www.bain.com/insights/covid-19-accelerates-the-adoption-of-telemedicine-in-asia-pacific-countries/>

² Australian Government Department of Health, Therapeutic Goods Administration, 31 October 2017, *Final decisions and reasons for decisions by delegates of the Secretary to the Department of Health*, accessed on 22 May 2020, <https://www.tga.gov.au/sites/default/files/final-decision-and-reasons-for-decision-by-delegate-october-2017.pdf>.

We are eager to develop the telemedicine channel for iX products as we believe that after this crisis, these digital health platforms which are currently disrupting traditional health care delivery will become a permanent and well-accepted part of the healthcare ecosystem. Therefore, we are delighted that despite the current challenges, our sales team is able to identify yet another distribution channel and lay the foundations for growth.”

In April 2020, iX Biopharma announced that it had out-licensed the right to distribute Wafesil[®] in China to Yiling Pharmaceutical Ltd. Preparations to register Wafesil[®] in China are underway. iX Biopharma has applied to the European Medicines Agency (EMA) for the registration of Wafesil[®] in Europe, where sildenafil can be supplied over-the-counter in certain countries in addition to via prescription. Silcap[®] has also been filed for registration with the Health Sciences Authority in Singapore.

Wafesil[®] is a novel dosage form of sildenafil and the only sildenafil product in Australia which is sublingually administered. It is formulated using iX Biopharma's patented sublingual drug delivery technology, WaferiX[®], and has the potential for better absorption and faster onset of therapeutic action. Silcap[®] is the only small capsule sildenafil product in Australia and is an alternative for patients who do not like to swallow tablets.

- The End -

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products through more than 200 pharmacies and health food shops in Australia and online.

Contact for media:**Dr Janakan Krishnarajah**

Chief Operating Officer and Chief Medical Officer

T: +65 6235 2270

E: j.krishnarajah@ixbiopharma.com**Eva Tan**

Director, Corporate and Commercial Strategy

T: +65 6235 3212

E: eva.tan@ixbiopharma.com**Investor Relations:****Kamal Samuel/James Bywater/Jonathan Wee**

T: +65 6438 2990

E: Tech@financialpr.com.sg

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.